Table 2.
First Author and Year | Overall Population | Positive (High) Number (Rate) | Markers | Definition of CIMP Status | Methods | TNM Stage | Evaluated Treatment | Response (Evaluation index) |
---|---|---|---|---|---|---|---|---|
Zhang XF. (27) | 125 | 27 (21.6%) | CIMP(CACNA1G, IGF2, NEUROG, RUNX3, SOCS1) | ≥3/5 loci | MSP | IV | Cetuximab or Panitumumab | A tendency of negative efficacy (PFS, OS) |
Gallois C. (31) | 1867 | 275(14.7%) | CIMP(CACNA1G, IGF2, NEUROG, RUNX3, SOCS1) | ≥3/5 loci | MSP | III | Cetuximab | A tendency of negative efficacy (OS, DFS, SAR) |
Ouchi K. (41) | 97(45/52) | 17(37.8%) 17(32.7%) | 485577 CpG sites | HMCC: CIMP-H LMCC: CIMP-L | Genome-wide DNA methylation | IV | Cetuximab or Panitumumab | Negative efficacy (OS, PFS, DCR,ORR) |
CIMP, CpG island methylator phenotype; MSP, methylation-specific polymerase chain reaction; HMCC, Highly methylated colorectal cancer;
LMCC, Low methylated colorectal cancer; DFS, disease-free survival; PFS, progression-free survival; SAR, survival after recurrence; OS, overall survival;
DCR, disease control rate; ORR, objective response rate.